Apnimed Prices Upsized Initial Public Offering
Apnimed, Inc. has priced its initial public offering (IPO) with an upsized number of shares. The clinical-stage pharmaceutical company focuses on oral therapies for sleep-related breathing disorders.
CAMBRIDGE, Mass. – July 30, 2026 – Apnimed, Inc., a biopharmaceutical company developing oral treatments for sleep-related breathing disorders, announced Thursday the pricing of its initial public offering. The company intends to sell an increased number of shares compared to its initial plans.
The offering will provide Apnimed with capital to fund its late-stage clinical trials and commercialization efforts. The company's lead drug candidate is designed to address the underlying neurobiology of conditions like obstructive sleep apnea. This marks a significant step for Apnimed as it seeks to bring its therapies to market.
Details regarding the exact number of shares offered and the price per share were disclosed in regulatory filings. The successful pricing of the IPO is crucial for Apnimed's ability to advance its pipeline and potentially offer new treatment options for patients suffering from sleep disorders.
Apnimed has been working to develop non-surgical, non-device oral medications. The company aims to address a significant unmet need in a market currently dominated by continuous positive airway pressure (CPAP) machines and surgical interventions.